A detailed history of Bank Of America Corp transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 5,940 shares of GLSI stock, worth $72,230. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,940
Previous 6,328 6.13%
Holding current value
$72,230
Previous $109,000 22.02%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.99 - $17.58 $5,040 - $6,821
-388 Reduced 6.13%
5,940 $85,000
Q2 2024

Aug 14, 2024

BUY
$12.07 - $19.04 $8,364 - $13,194
693 Added 12.3%
6,328 $109,000
Q1 2024

May 15, 2024

BUY
$8.31 - $20.32 $6,589 - $16,113
793 Added 16.38%
5,635 $112,000
Q4 2023

Feb 14, 2024

SELL
$7.77 - $12.3 $1,693 - $2,681
-218 Reduced 4.31%
4,842 $50,000
Q2 2023

Aug 14, 2023

SELL
$9.58 - $13.2 $6,734 - $9,279
-703 Reduced 12.2%
5,060 $48,000
Q1 2023

May 12, 2023

SELL
$12.12 - $20.8 $44,201 - $75,857
-3,647 Reduced 38.76%
5,763 $79,000
Q4 2022

Feb 10, 2023

SELL
$9.04 - $16.88 $60,125 - $112,268
-6,651 Reduced 41.41%
9,410 $143,000
Q3 2022

Nov 14, 2022

BUY
$7.81 - $12.02 $42,298 - $65,100
5,416 Added 50.88%
16,061 $146,000
Q2 2022

Aug 12, 2022

BUY
$7.14 - $20.36 $31,644 - $90,235
4,432 Added 71.33%
10,645 $90,000
Q1 2022

May 16, 2022

BUY
$16.3 - $24.65 $50,693 - $76,661
3,110 Added 100.23%
6,213 $122,000
Q4 2021

Feb 08, 2022

BUY
$21.76 - $39.43 $25,067 - $45,423
1,152 Added 59.05%
3,103 $76,000
Q3 2021

Nov 15, 2021

BUY
$38.65 - $46.11 $45,645 - $54,455
1,181 Added 153.38%
1,951 $76,000
Q2 2021

Sep 13, 2021

BUY
$31.24 - $53.6 $24,054 - $41,272
770 New
770 $35,000

Others Institutions Holding GLSI

About Greenwich LifeSciences, Inc.


  • Ticker GLSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,848,200
  • Market Cap $156M
  • Description
  • Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...
More about GLSI
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.